Primary Thrombocythaemia 1 Trial

NACompletedINTERVENTIONAL
Enrollment

1,398

Participants

Timeline

Start Date

July 31, 1997

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
ThrombocythemiaMyeloproliferative Disorder
Interventions
DRUG

Hydroxyurea

Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.

DRUG

Aspirin

Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.

Trial Locations (1)

CB2 2QQ

Addenbrooke's Hospital, Cambridge

All Listed Sponsors
collaborator

Cambridge University Hospitals NHS Foundation Trust

OTHER

collaborator

Institute of Cancer Research, United Kingdom

OTHER

lead

University of Cambridge

OTHER

NCT00175838 - Primary Thrombocythaemia 1 Trial | Biotech Hunter | Biotech Hunter